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Trial (HYVET) trials, 23 and ACE inhibitors and calcium channel blockers (CCBs), as in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) 24 and Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) 20 trial. In this context, the ADVANCE trial provides us with an opportunity to examine the possible advantages of a triple combination for which there are as yet no randomized data from cardiovascular outcome trials. In this trial, the study drugs were the ACE inhibitor perindopril and the diuretic indapamide, used in fixed combination. 19 In this article, we compare the effects of randomized treatment with the combination of perindopril and indapamide in subgroups defined by use of CCBs at baseline. Specifically, we examine the effects on major cardiovascular events (the primary outcome), cardiovascular death, and all-cause mortality. We also report observational analyses comparing the effects of randomized treatment, with the fixed combination of perindopril and indapamide, in subgroups defined by use of CCBs at any time, whether before or after randomization.
Methods
ADVANCE trial was a factorial randomized controlled trial of blood pressure lowering and intensive blood glucose control in patients with type 2 diabetes mellitus. Details of the design and procedures have been described previously. 19, 25 Patients were potentially eligible if they had been diagnosed with type 2 diabetes mellitus at the age of ≥30 years and were aged ≥55 years at entry to the study. Potentially eligible patients also needed to have ≥1 of the following: a history of major cardiovascular disease (stroke, myocardial infarction, hospital admission for transient ischemic attack, hospital admission for unstable angina, coronary revascularization, peripheral revascularization, or amputation secondary to vascular disease) or ≥1 other risk factor for cardiovascular disease. There were no blood pressure criteria for entry. Prior blood pressure-lowering medications were not required to be stopped at the start of the run-in period. Approval for the trial was obtained from each center's institutional review board, and all participants provided written informed consent.
Participants who tolerated ≥6 weeks of run-in therapy with fixed combination tablet consisting of perindopril (2 mg) and indapamide (0.625 mg) were randomly assigned, in a double-blind fashion, to fixed combination of perindopril and indapamide (2/0.625 mg for the first 3 months and 4/1.25 mg thereafter) or matching placebo.
Information on use of CCBs (any dihydropyridine or nondihydropyridine) was collected at baseline and follow-up visits.
The outcomes for the present analysis were major cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death), cardiovascular death, and death from any cause.
Statistical Analysis
The effects of randomized treatment on events were calculated using univariate Cox proportional hazards models, according to the principle of intention-to-treat. The effects of randomized treatment on blood pressure were estimated using linear mixed models. Comparisons of treatment effects between subgroups were examined by adding an interaction term to the statistical models. Drug effects were also estimated from observational analyses that used Cox proportional hazards models after adjustment for wide variety of covariates as described in the legends of Figures and Tables. Percentage risk reductions were calculated as ([1−hazard ratio]×100). All P values were calculated from 2-tailed tests of statistical significance.
Results
Analyses of Randomized Data
A total of 11 140 patients with type 2 diabetes mellitus were randomized into the blood pressure arm of ADVANCE trial, with 5569 assigned to active treatment with the fixed combination of perindopril and indapamide and 5571 to matching placebo. 19 Of these, 3427 (1669 in active group and 1758 in placebo group) were taking a CCB and 7713 (3900 in active group and 3813 in placebo group) were not at baseline. The mean duration of follow-up was 4.3 years. The characteristics of these patients at baseline are shown in Table 1 . Those on CCB represent a higher risk group with longer duration of diabetes mellitus, higher systolic and diastolic blood pressures despite higher rates of treatment with antihypertensive drugs, and higher rates of previous cardiovascular disease.
The mean difference in systolic blood pressure between those on active treatment and those on placebo, across the whole period of randomized treatment, was 4.7 mm Hg (95% confidence interval, 3.8-5.6) in those on CCB and 6.2 mm Hg (5.5-6.8) in those not on CCB, reflecting the greater difficulty of lowering blood pressure in a higher risk group of patients that was receiving more extensive antihypertensive therapy (Tables 1 and 2 ). Figure 1 shows the effects of randomized treatment in subgroups defined by use of CCBs at baseline. Active treatment with the fixed combination of perindopril and indapamide reduced the relative risk of death by 28% (10%-43%) among patients with CCB compared with 5% (−12% to 20%) among those without CCB (P homogeneity=0.02) and 14% (2%-25%) for the whole population ( Figure 1 ). There were also trends, although not significant, for greater reductions in major cardiovascular events and cardiovascular mortality ( Figure 1 ).
Analyses of Observational Data
We compared the effects of blood pressure lowering in the group assigned to randomized treatment with the fixed combination of perindopril and indapamide who received CCBs at any time point (whether at baseline or during follow-up) with effects in the group assigned to placebo who did not receive CCBs at any time, whether before or after randomization. The baseline characteristics of those 2 groups are shown in Table  S1 in the online-only Data Supplement. Once again, the group receiving CCBs was a higher risk group. As can be seen in Figure 2 , after adjustment, those receiving active treatment plus CCBs had substantial and significant reductions in both all-cause mortality and cardiovascular death.
We also compared the effects of blood pressure lowering in the group assigned to randomized treatment with the fixed combination of perindopril and indapamide who also received CCBs at baseline with effects in the group assigned to placebo who also received open-label perindopril and a CCB. The baseline characteristics of those 2 groups are shown in Table S2 . As can be seen in Figure 3 , after adjustment, the group receiving the triple therapy with ACE inhibitor, diuretic, and CCB had a significant reduction in all-cause mortality compared with the patients on dual therapy with CCB and ACE inhibitor. There was a nonsignificant trend to greater reduction in major cardiovascular events and cardiovascular death (Figure 3 ).
Permanent Discontinuation and Adverse Effects of Study Treatment
The frequency of permanent discontinuation and key adverse effects among patients assigned active treatment and those assigned placebo are reported by baseline use of CCBs in Table  S3 . Compared with participants who did not receive CCBs at baseline, there was no clear increase in the frequency of total permanent discontinuation or of discontinuation attributable to adverse effects such as hypotension and cough among those on CCBs at baseline for both active and placebo groups.
Discussion
The present analyses in patients with type 2 diabetes mellitus indicate that adding a CCB to the combination of an ACE inhibitor and a diuretic produces additional tangible benefits. Thus, being on a CCB as well as the fixed combination of perindopril and indapamide in patients participating in ADVANCE trial led to significantly greater reductions in all-cause mortality, with nonsignificant trends to greater reduction in cardiovascular mortality and major cardiovascular events, than being on the fixed combination alone. Furthermore, these benefits seemed to be independent of the degree of blood pressure reduction and were observed despite the greater risk profile of the patients receiving CCB, either at baseline or during follow-up.
The best combinations of blood pressure-lowering drugs combine different primary actions so as to achieve fully Hazard ratios and P values were adjusted for age, sex, duration of diabetes mellitus, systolic blood pressure, hemoglobin A1c, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, log-transformed triglyceride, estimated glomerular filtration rate, urinary albumin-creatinine ratio, body mass index, smoking, ECG abnormalities, and randomized treatments. 95% CI indicates 95% confidence interval; and CCB, calcium channel blocker. additive effects on blood pressure reduction. At the same time, the combination of ≥2 drugs enables the use of each drug either in standard dose or even in low dose, thus reducing the frequency of side effects and enhancing acceptability and adherence to therapy. [8] [9] [10] [11] 13, 26 Two of the most favored combinations in the modern era are the use of ACE inhibitors with diuretics and the use of ACE inhibitors with CCBs. The former has the advantage of opposing effects on potassium secretion by the kidneys, thus minimizing the risks of hyper-or hypokalemia. This combination has been shown to have outstanding effects on mortality and hard cardiovascular outcomes in the PROGRESS, 22 ADVANCE, 19 and HYVET trials 23 in which the ACE inhibitor was perindopril and the diuretic was indapamide. The combination of ACE inhibitors with CCBs also has additive effects on blood pressure lowering and has been amply vindicated by the ASCOT which achieved excellent results on hard outcomes, using perindopril and amlodipine 24 and the ACCOMPLISH trial using benazepril and amlodipine, on a range of cardiovascular outcomes. 20 The present analyses indicate that when a third drug is necessary, the combination of an ACE inhibitor, a diuretic, and a CCB provides an excellent 3-fold option to reduce the risk of death and major cardiovascular events with low rates of adverse events. Furthermore, the triple combination of perindopril, indapamide, and a CCB seems superior to the double combination of either perindopril and indapamide alone (Figure 1 ) or perindopril and a CCB (Figure 3 ).
Many guidelines for management of hypertension recommend combination antihypertensive therapy for patients with hypertension and also for patients with high cardiovascular risk, whether hypertensive or not. [8] [9] [10] [11] 13 However, one of the biggest dilemmas in our field continues to be the great gap between evidence and practice, with low levels of achievement of recommended blood pressure targets worldwide. [2] [3] [4] [5] [6] [7] One possible reason for the resistance of both patients and community physicians against combination therapy is likely to be the increase in the number of antihypertensive agents. There is considerable evidence that use of fixed-dose (singlepill) combinations of 2, 3, or even more blood pressure-lowering agents may result in better adherence to medications and subsequent better blood pressure control. [14] [15] [16] 18, 21, 27 In the present analysis, the effects of active treatment with the fixed combination of perindopril and indapamide on total mortality were larger among patients with CCB compared with those without CCB, with nonsignificant trend for the outcome of cardiovascular death. It is difficult to explain the reasons for this finding clearly, but it should be noted that the main results of ADVANCE trial reported major reductions in allcause mortality (14%) and cardiovascular mortality (18%). 19 In addition, possible imbalance in unknown confounding factors may have contributed to these findings.
The analyses reported here have the advantage of being based on a large-scale clinical trial with sufficient power to examine the effects of randomized treatment in a variety of subgroups Figure 2 . Effects of the combination of perindopril and indapamide (randomized study drugs) with calcium channel blockers (CCBs) at any visit (nonstudy drug) on major cardiovascular (CV) events and death compared with participants on placebo who never received CCBs. Solid boxes represent estimates of treatment effect on the risk of clinical outcomes. Centers of the boxes are placed at the estimates of effect; areas of the boxes are proportional to the reciprocal of the variance of the estimates. Horizontal lines represent 95% confidence interval (CI). Hazard ratios and P values were adjusted for age, sex, duration of diabetes mellitus, systolic blood pressure, hemoglobin A1c, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, log-transformed triglyceride, estimated glomerular filtration rate, urinary albumin-creatinine ratio, body mass index, smoking, ECG abnormalities, and randomized glucoselowering treatment. Figure 3 . Effects of the combination of perindopril and indapamide (randomized study drugs) with calcium channel blockers (CCBs) at baseline (nonstudy drug) on major cardiovascular (CV) events and death compared with participants on placebo who received nonrandomized perindopril and CCBs at baseline (nonstudy drugs). Solid boxes represent estimates of treatment effect on the risk of clinical outcomes. Centers of the boxes are placed at the estimates of effect; areas of the boxes are proportional to the reciprocal of the variance of the estimates. Horizontal lines represent 95% confidence interval (CI). Hazard ratios and P values were adjusted for age, sex, duration of diabetes mellitus, systolic blood pressure, hemoglobin A1c, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, log-transformed triglyceride, estimated glomerular filtration rate, urinary albumin-creatinine ratio, body mass index, smoking, ECG abnormalities, and randomized glucose-lowering treatment.
by guest on September 13, 2017 http://hyper.ahajournals.org/ Downloaded from defined by baseline characteristics, in this instance the use of CCBs or not. The analyses also have several limitations. They are all post hoc, and none were prespecified at the time the ADVANCE trial was designed. Because the use of CCB was not randomly assigned, there was significant heterogeneity in baseline characteristics and in the risks of cardiovascular events and deaths between patients with and without CCB. Furthermore, some analyses are based on observational data and lose the advantage of unbiased randomized comparison.
Perspectives
The addition of CCBs to the combination of the ACE inhibitor perindopril with the diuretic indapamide seems to enhance the reduction of all-cause mortality and hard cardiovascular outcomes in patients with type 2 diabetes mellitus in ADVANCE trial. These potential benefits were seen without any detectable increase in adverse events.
Sources of Funding
The ADVANCE trial was funded by grants from the National Health and Medical Research Council (NHMRC) of Australia and Servier International. What Is New?
• These analyses present the first evidence from randomized data that the use of a triple combination of antihypertensive agents (angiotensinconverting enzyme inhibitor+diuretic+calcium channel blocker) is more effective than a double combination (angiotensin-converting enzyme inhibitor+diuretic) in reducing mortality.
What Is Relevant?
• Combination therapy is recommended by most guidelines to improve control of hypertension worldwide, but there is so far little evidence of the benefits of triple combinations on hard end points.
Summary
The combination of perindopril and indapamide with calcium channel blockers seems to provide further protection against mortality in patients with type 2 diabetes mellitus. This article provides the first report of improvement in hard end points in patients receiving the combination of 3 antihypertensive drugs compared with those on 2 drugs. Table S1 . Baseline characteristics of participants on combination therapy of perindopril and indapamide (randomised drugs) who received CCB at any visit (non-study drug) and of those on placebo who never received CCB
Novelty and Significance
